138 related articles for article (PubMed ID: 16359437)
1. New strategies for the medical treatment of prostate cancer.
Isaacs JT
BJU Int; 2005 Dec; 96 Suppl 2():35-40. PubMed ID: 16359437
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapeutic approaches for hormone-refractory prostate cancer.
Stavridi F; Karapanagiotou EM; Syrigos KN
Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
[TBL] [Abstract][Full Text] [Related]
3. Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.
Khatri A; Russell PJ
Discov Med; 2007 Feb; 7(37):39-45. PubMed ID: 17343804
[TBL] [Abstract][Full Text] [Related]
4. [Targeted therapies for hormone-refractory prostate cancer].
Song HZ; Chen LB
Zhonghua Nan Ke Xue; 2010 Dec; 16(12):1108-12. PubMed ID: 21348204
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
6. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
Miyake H; Hara I; Gleave ME
Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
[TBL] [Abstract][Full Text] [Related]
8. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer.
Uemura M; Tamura K; Chung S; Honma S; Okuyama A; Nakamura Y; Nakagawa H
Cancer Sci; 2008 Jan; 99(1):81-6. PubMed ID: 17986282
[TBL] [Abstract][Full Text] [Related]
9. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
[TBL] [Abstract][Full Text] [Related]
10. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
11. The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer.
Arnoldussen YJ; Lorenzo PI; Pretorius ME; Waehre H; Risberg B; Maelandsmo GM; Danielsen HE; Saatcioglu F
Cancer Res; 2008 Nov; 68(22):9255-64. PubMed ID: 19010898
[TBL] [Abstract][Full Text] [Related]
12. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
Berry W; Eisenberger M
Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
[TBL] [Abstract][Full Text] [Related]
13. Novel targets and approaches in advanced prostate cancer.
Hadaschik BA; Sowery RD; Gleave ME
Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic approach to hormone-refractory prostate cancer.
Saad F; Al Dejmah A; Perrotte P; McCormack M; Bénard F; Valiquette L; Karakiewicz PI
Can J Urol; 2006 Apr; 13 Suppl 2():52-6. PubMed ID: 16672130
[TBL] [Abstract][Full Text] [Related]
15. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
[TBL] [Abstract][Full Text] [Related]
16. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
Di Lorenzo G; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
[TBL] [Abstract][Full Text] [Related]
17. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells.
Srinivasan S; Ranga RS; Burikhanov R; Han SS; Chendil D
Cancer Res; 2007 Jan; 67(1):246-53. PubMed ID: 17185378
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer.
Flaig TW; Barqawi A; Miller G; Kane M; Zeng C; Crawford ED; Glodé LM
Cancer; 2006 Jul; 107(2):266-74. PubMed ID: 16779800
[TBL] [Abstract][Full Text] [Related]
19. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
Heng DY; Chi KN
Can J Urol; 2006 Dec; 13(6):3335-9. PubMed ID: 17187697
[TBL] [Abstract][Full Text] [Related]
20. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
